Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
200 hedge funds and large institutions have $560M invested in Esperion Therapeutics in 2025 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 83 increasing their positions, 34 reducing their positions, and 28 closing their positions.
350% more call options, than puts
Call options by funds: $19.2M | Put options by funds: $4.26M
144% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 34
96% more capital invested
Capital invested by funds: $286M → $560M (+$274M)
54% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 28
9.73% more ownership
Funds ownership: 53.55% → 63.28% (+9.7%)
6% more funds holding
Funds holding: 188 → 200 (+12)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$21.6M |
| 2 |
O
OrbiMed
New York
|
+$19.3M |
| 3 |
EP
Eversept Partners
New York
|
+$12.4M |
| 4 |
Millennium Management
New York
|
+$9.56M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$9.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
PenderFund Capital Management
Vancouver,
British Columbia, Canada
|
-$7.38M |
| 2 |
IHAM
Integral Health Asset Management
New York
|
-$3.98M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.01M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.91M |
| 5 |
Jane Street
New York
|
-$2.82M |
ESPR Hedge Fund Activity: Q4 2025 in Review
200 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q4 2025, worth a combined $560M — up 96% from $286M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new ESPR positions and 28 closed out — a net gain of 15 holders — while 83 added to existing stakes and 34 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $21.6M. The largest seller was PenderFund Capital Management, cutting an estimated $7.38M.
- 200 institutional investors held Esperion Therapeutics (ESPR) as of Q4 2025, up from 188 in Q3 2025.
- Funds reported $560M of Esperion Therapeutics stock for Q4 2025, up 96% quarter-over-quarter.
- 43 funds opened new Esperion Therapeutics positions in Q4 2025 and 28 closed out, a net change of +15 holders.
- The largest Esperion Therapeutics buyer in Q4 2025 was D.E. Shaw & Co, an estimated $21.6M added.
- The largest Esperion Therapeutics seller in Q4 2025 was PenderFund Capital Management, an estimated $7.38M sold.
Based on aggregated 13F filings for Q4 2025.